David H Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Major win for patients with muscle-invasive bladder cancer!
The FDA has approved EV + Pembrolizumab as perioperative therapy for patients who are cisplatin-ineligible — a huge step forward in improving outcomes and expanding treatment options.
Read the full FDA announcement.”
You can also read: FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
